🧬 Aging Wiki

biostimulatory-fillers

Properties1
aliasesbiostimulators, biostimulatory fillers, collagen-stimulating injectables, PLLA, Sculptra, PCL, Ellansé, PDO, CaHA, Radiesse, poly-L-lactic acid, polycaprolactone, polydioxanone, calcium hydroxylapatite, PDLLA

25 min read

Biostimulatory Fillers (Collagen-Stimulating Injectables)

TL;DR. Biostimulatory fillers are a class of biodegradable synthetic polymer particles — poly-L-lactic acid (PLLA), poly-D,L-lactic acid (PDLLA), polycaprolactone (PCL), polydioxanone (PDO), and calcium hydroxylapatite microspheres (CaHA) — injected intradermally or subdermally to trigger a controlled foreign-body inflammatory response that ultimately drives sustained dermal fibroblast activation and neocollagenesis. Unlike hyaluronic-acid fillers (space-filling and hydration) or PDRN/polynucleotides (adenosine A2A receptor-mediated pathway), biostimulators work by a scaffold-dependent physical mechanism: polymer particles are phagocytosed by macrophages, setting off an M1→M2 polarization sequence that eventually floods surrounding fibroblasts with TGF-β and FGF, driving sustained upregulation of type I collagen and type III collagen. The result — durable neocollagenesis over months-to-years as the scaffold degrades — is histologically demonstrated and underlies FDA approval of PLLA (Sculptra) and CaHA (Radiesse). The evidence base, however, is dominated by small uncontrolled or non-blinded studies; no sham-injection-controlled RCT with histological endpoints exists for any agent in this class. Effect sizes relative to the needle-wound stimulus remain unquantified.

This page is the class home for all five biodegradable-polymer biostimulators. Individual compound-level pages may be seeded later; each subsection here carries #stub where a dedicated page would be appropriate. The umbrella context (classification scheme, comparison with HA/PDRN, injection technique, regulatory overview) lives on injectable-skin-boosters.

Disambiguation: CaHA and vascular calcification. “Calcium hydroxylapatite” also appears extensively in this wiki in the context of vascular calcification (arterial CaHA deposits, matrix-gla-protein, ectopic mineralization). Those pages concern an entirely different biological phenomenon — endogenous calcium-phosphate mineral deposition in tissues, a feature of aging arteries. The CaHA filler (Radiesse) is a synthetic exogenous product of 25–45 μm microspheres in a carboxymethylcellulose gel, injected for aesthetic volume and biostimulation. Do not cross-wire this page to vascular-calcification pages.

Shared mechanism: foreign-body → M1→M2 → neocollagenesis

All five agents in this class share a common mechanistic architecture, with important quantitative and kinetic differences. The sequence has three phases 12:

Phase 1 — Acute inflammatory recruitment (days 1–14). Polymer particles injected into the dermis are opsonized and engulfed (or at least peripherally contacted) by macrophages. A classically activated M1 macrophage state is triggered, producing pro-inflammatory cytokines. For PLLA, the specific M1 cytokines elevated are CCL1, TNFR2, MIP-1α, and IL-8 (all P<0.05 vs. CaHA and unstimulated controls) 3. For PLLA-SCA specifically, upregulation of IL1B and CXCL6 is observed in 3D skin models, with IL1B identified as a potential mediator of downstream collagen I synthesis 4.

Phase 2 — Macrophage polarization and fibroblast activation (weeks 2–8). M1 macrophages polarize to M2 phenotype (IL-4/IL-13/TGF-β milieu); M2-conditioned paracrine signals, principally TGF-β1, activate surrounding dermal-fibroblasts via SMAD2/3 phosphorylation. FGF2 provides a co-stimulatory proliferative signal. PLLA and PDLLA both drive a sustained M1→M2 transition with upregulation of type I and III collagen and elastin 12. CaHA exhibits a more pronounced early inflammatory gene signature but with rapid resolution 2. In PLLA in-vivo rat studies, type III collagen is predominantly stimulated early, with type I collagen predominating in later stages as fibroblasts differentiate toward myofibroblasts 5.

Phase 3 — Progressive polymer degradation and structural consolidation (months to years). As the polymer scaffold hydrolyzes (via ester-bond hydrolysis by tissue water), newly synthesized collagen fills the volume previously occupied by particles. The duration of this phase varies markedly by polymer crystallinity and chain length (see per-agent subsections). CaHA degrades by dissolution of the mineral phase, releasing Ca²⁺ ions that may independently stimulate fibroblast activity 1.

Contrast with other injectable skin booster mechanisms:

Agent classPrimary mechanismKey molecular eventDegradation timeline
HA fillersSpace-filling + hygroscopic hydrationNone (structural)Weeks to months (HYAL)
PDRN/PNAdenosine A2A receptor agonism → PCK1 → M2 macrophagecAMP/CREB/PCK1 axisNot applicable (nucleotides absorbed)
PLLA / PDLLA / PCL / PDOForeign body → M1→M2 macrophage → TGF-β/FGF → SMADSMAD2/3 phosphorylation1–4 years
CaHAAs above + Ca²⁺ fibroblast stimulationTGF-β/SMAD + Ca²⁺ signalling~12–18 months
DimensionStatus
M1→M2→fibroblast TGF-β axis conserved in humans?Yes — human macrophage in vitro confirmed 34
SMAD-driven collagen I/III induction in aged human dermis?Demonstrated in vitro/animal 5; not yet in placebo-controlled human biopsy RCT
Replicated with sham-controlled histological endpoint in humans?No gap/needs-replication

PLLA — poly-L-lactic acid (Sculptra)

Identity and physical properties

PLLA is a semicrystalline polylactic acid polymer with regular stereochemical arrangement of L-isomer lactide units. Semicrystallinity confers slower hydrolytic degradation compared to the fully amorphous PDLLA form — PLLA degrades over approximately 12–18 months in tissue. Commercial PLLA (Sculptra; Galderma) is supplied as lyophilized microparticles reconstituted in sterile water; standard reconstitution volume has evolved from the original 3–5 mL (the era of high nodule incidence) to current recommendations of 8–10 mL or more for facial applications.

Regulatory status. Sculptra is FDA-approved for correction of facial fat loss (lipoatrophy) in HIV-positive patients (2004) and subsequently for correction of shallow-to-deep nasolabial fold contour deficiencies and facial wrinkles in immunocompetent patients (2009). It is also CE-marked. gap/needs-canonical-id — FDA 510(k)/PMA clearance number not verified in this session.

Mechanism-specific findings

PLLA-specific M1 macrophage activation induces CCL1, TNFR2, MIP-1α, and IL-8 as the dominant early cytokine signature (in vitro, primary human macrophages) 3. In a macrophage-containing 3D skin model, PLLA-SCA upregulated TGFB2 and CXCL6 at day 14 and increased epidermal thickness, with IL1B driving CXCL6-mediated collagen I synthesis 4. In vivo rat studies show early type III collagen induction transitioning to type I predominance as fibroblasts differentiate to myofibroblasts 5. gap/needs-human-replication — all histological endpoints are from in vitro models or rodents; human biopsy data post-PLLA injection is limited to uncontrolled histological case series.

Nodule risk — protocol evolution

Nodule formation is the signature complication of PLLA. The intradermal injection technique used in the original HIV-lipoatrophy era produced noninflammatory nodules (2–4 mm) in 12 of 94 patients (12.8%) within 2–9 months post-injection (Lafaurie M et al. 2005, J Acquir Immune Defic Syndr 38(4):393-398, Rho 2024 ref [55]) 1. gap/needs-replication — primary DOI for Lafaurie 2005 not independently confirmed against full text in this session; sourced via Rho 2024.

With the transition to deep subcutaneous placement, high-volume reconstitution (≥8 mL), and strict avoidance of injecting around the eyes and lips, a large US retrospective study across multiple centers (4,483 treatments in 1,002 subjects; Palm M, Mayoral F, Rajani A et al., J Drugs Dermatol 2021;20(1):118-122, Rho 2024 ref [57]) reported only 0.4% PLLA nodule incidence 1. gap/needs-replication — primary DOI for Palm/Mayoral 2021 not independently confirmed against full text in this session; sourced via Rho 2024. The absolute magnitude of improvement (12.8% → 0.4%) is consistent with the clinical consensus on protocol evolution.

Sonicated PLLA at approximately 40 μm particle size is reported to improve atrophic acne scars without nodule formation in a Korean series 1. gap/needs-replication gap/needs-canonical-id.

A Korean two-year study combining intradermal PLLA with microneedle radiofrequency reported no nodule events over the observation period 1. gap/needs-replication — primary DOI not confirmed in this session.

Safety notes on the Brazilian real-world data (relevant to all biostimulators, most nodule cases were PLLA + PCL): in 55 biostimulator complication cases captured by ultrasound experts in Brazil, nodule formation was the dominant event; only 5/55 cases showed complete resolution across all treatment attempts; enzymatic dissolution was specifically effective for CaHA-HA combinations but not pure PLLA or PCL nodules 6.

PDLLA — poly-D,L-lactic acid

Identity and physical properties

PDLLA is the racemic amorphous form of polylactic acid (mixture of D- and L-lactide units), in contrast to the semicrystalline PLLA. Amorphous structure means faster and more uniform hydrolytic degradation compared to PLLA, and a more consistent spherical particle morphology. Commercially available as Sculptra Dilution Extended Protocol formulations and standalone PDLLA products in some markets (Juvelook, AESTHEFILL). Not separately FDA-approved in the US as distinct from PLLA; CE-marked formulations available.

Mechanism-specific findings

PDLLA shares the M1→M2 macrophage polarization pathway with PLLA. Distinctive features reported include: upregulation of NRF2 in macrophages (implying a partial oxidative-stress-buffering response in addition to the TGF-β axis) 1; enhanced adipose-derived stem cell (ADSC) proliferation with upregulation of TGF-β and FGF2 1; and a reported volume-building effect that increases over time (consistent with the scaffold-fill mechanism). “Super-thin” dilutions (12–24 mL water per vial equivalent) have been proposed for shallow wrinkle treatment in smaller volumes 1. gap/needs-canonical-id for these mechanistic claims — DOIs for NRF2 and ADSC findings were not independently located in this session.

DimensionStatus
Mechanism conserved in humans?M1→M2 pathway conserved; NRF2/ADSC details are in vitro only 1
Phenotype (neocollagenesis) conserved in humans?Plausible; no sham-controlled human biopsy RCT
Replicated in humans?Small uncontrolled series only gap/needs-human-replication

stub — PDLLA warrants its own compound page if dedicated clinical trial data accrues; current evidence does not differentiate it from PLLA at the human-evidence level.

PCL — polycaprolactone (Ellansé)

Identity and physical properties

Polycaprolactone is a semicrystalline polyester with slower hydrolytic degradation than PLLA (ester bond hydrolysis rate lower due to longer aliphatic chain between ester groups). Ellansé microspheres are 25–50 μm, suspended in carboxymethylcellulose gel carrier. Ellansé is available in four durability variants (S: ~1 yr; M: ~2 yr; L: ~3 yr; E: ~4 yr) differing in molecular weight and crystallinity. CE-marked in the EU. Not FDA-cleared as a filler in the United States; FDA cleared a different PCL-based product (Radiesse competitor context only) — Ellansé is commercially available in Europe, South Korea, South America, and parts of Asia. gap/needs-canonical-id — FDA clearance status for PCL fillers in the US should be verified against the FDA device database.

Mechanism-specific findings

PCL induces a foreign-body granulomatous response with greater fibroblast proliferation, growth, migration, adhesion, and angiogenesis compared to CaHA in animal models 1. In vitro and in vivo animal data show 25–50 μm PCL microspheres integrate with new type I collagen 1. gap/needs-human-replication — specific comparative studies (PCL > CaHA for fibroblast proliferation) are from animal models; primary DOIs not independently confirmed in this session.

A Korean study (Kim JS, Aesthet Surg J 2019;39(12):NP484-NP494, Rho 2024 ref [67]) reported that a single intradermal PCL injection produced +27% temporal skin thickness and +21% facial skin thickness at one year, measured by high-frequency ultrasound (skin biopsy histology) 1. gap/needs-replication — primary DOI for Kim JS 2019 not independently confirmed against full text in this session; study design details (n, control arm) are unclear from the Rho review summary.

A 4-year longitudinal study of Ellansé (Kim J., Plast Reconstr Surg Glob Open 2020;8(6):e2866, Rho 2024 ref [68]) reported that particles retain approximately 95% of their initial size through year 3, with size reduction and surface texture changes (smooth to rough) occurring in year 4 1. gap/needs-replication — primary DOI for Kim J. 2020 not independently confirmed against full text in this session. Timeline consistent with known degradation kinetics of high-MW crystalline PCL.

In rat models, no significant inflammatory infiltration was observed with PCL beyond the initial foreign-body reaction phase, suggesting a more quiescent inflammatory profile than PLLA after the initial biostimulatory window 1. PCL-induced neocollagenesis is reported to last up to 24 months 2.

DimensionStatus
Fibroblast activation pathway conserved in humans?Foreign-body TGF-β/FGF axis is conserved; species-specific differences in inflammatory profile possible
Skin thickness gain demonstrated in aged human dermis?Claimed in uncontrolled Korean series; no blinded measurement vs sham 1 gap/needs-replication
Long-term (>4 yr) degradation status?Not established; 4-yr study data is the current outer bound gap/long-term-unknown

Late granuloma formation is documented with PCL, though considered uncommon with correct injection technique. The 55-case Brazilian complication series 6 captured PCL nodules as one of the three dominant biostimulator complication types. stub — PCL deserves its own compound page when more phase-2 or phase-3 controlled trial data exists.

PDO — polydioxanone

Identity and physical properties

Polydioxanone is the most rapidly biodegradable polymer in this class: complete in-tissue hydrolysis is reported in approximately 6 months. PDO is also used as absorbable surgical sutures (“PDO threads”), and the thread-lifting application is distinct from the microsphere-filler application covered here. PDO microspheres self-disperse more readily in tissue than PLLA or PCL particles 1.

Regulatory status. PDO microsphere fillers are CE-marked in the EU and available in South Korea. Not FDA-cleared as a standalone dermal filler in the United States.

Mechanism-specific findings

PDO triggers neocollagenesis and a controlled inflammatory response similar in profile to PLLA and PCL. A comparative preclinical study (Kim CM et al. 2019, J Cosmet Dermatol 18(06):1893-1898, Rho 2024 ref [80]) found PDO superior to PLLA for induction of Col1α1, Col3α1, TGF-β2, and TGF-β3 in a murine collagen production model 17. gap/needs-replication — primary DOI not independently confirmed against full text in this session; source is Rho 2024 ref [80] = Kim CM et al. 2019. Note: the retracted Zhou et al. 2023 paper (PMID 37103107; Rho ref [79]) is excluded from citation here; the comparative collagen/TGF-β claim traces to Kim CM 2019 (non-retracted), not to Zhou 2023. 8

Particle area for PDO decreases over 3 months in tissue, consistent with the faster hydrolysis profile 1.

DimensionStatus
Neocollagenesis mechanism conserved in humans?Foreign-body TGF-β axis shared with all biostimulators; human-specific PDO data is sparse
Clinical evidence in aged human skin?Small uncontrolled clinical series only gap/needs-human-replication
Long-term benefit beyond polymer degradation?Unknown — the faster degradation of PDO raises the question of durability; no RCT data gap/long-term-unknown

stub — PDO microsphere filler warrants its own page when the Kim CM 2019 comparative study and any subsequent replications are independently verified; the TGF-β/collagen superiority claim over PLLA is plausible but rests on a single unconfirmed murine study.

CaHA — calcium hydroxylapatite (Radiesse)

DISAMBIGUATION — this is the aesthetic filler, not vascular calcification

See the disambiguation notice at the top of this page. The calcium hydroxylapatite discussed here is Radiesse, a synthetic injectable of 25–45 μm CaHA microspheres suspended in carboxymethylcellulose (CMC) gel. This has no mechanistic or biological relationship to the endogenous calcium-phosphate mineral deposits seen in atherosclerotic plaques or in calcified cartilage/kidney stone biology. Do not cross-wire to matrix-gla-protein or other vascular-calcification pages except to note the naming overlap.

Identity and physical properties

CaHA microspheres in the Radiesse formulation are 25–45 μm synthetic calcium hydroxylapatite in a CMC carrier gel. The CMC gel provides immediate volume augmentation that is resorbed over weeks; the CaHA microspheres degrade more slowly by phagocytosis and dissolution, releasing calcium and phosphate ions. Degradation timeline: CMC gel in weeks; CaHA microspheres in approximately 12–18 months 1.

Regulatory status. Radiesse is FDA-approved for correction of moderate-to-severe facial wrinkles and folds including nasolabial folds (original approval 2006), as well as for hand augmentation (supplemental approval 2015). CE-marked. This is one of two FDA-approved biostimulators (the other being PLLA/Sculptra). gap/needs-canonical-id — PMA number not confirmed in this session.

Mechanism-specific findings

CaHA acts by two complementary mechanisms: (1) the shared foreign-body TGF-β/FGF/SMAD neocollagenesis pathway shared with PLLA/PCL; and (2) a proposed Ca²⁺-direct fibroblast stimulation mechanism as microspheres dissolve 1. Nowag et al. 2024 found that CaHA induced a significantly lower early cytokine response than PLLA in primary human macrophages — specifically, none of the four cytokines elevated by PLLA (CCL1, TNFR2, MIP-1α, IL-8) were significantly upregulated by CaHA 3. This suggests CaHA’s biostimulatory mechanism is more fibroblast-direct (via Ca²⁺ and structural scaffold) and less macrophage-cytokine-mediated than PLLA.

In animal studies, CaHA produced lower fibroblast proliferation than PCL 1; Porcello et al. 2024 found that in primary fibroblast collagen synthesis assays, vitamin B3-HA hydrogels (HAR-1 and HAR-3) induced significantly greater total collagen production than Radiesse and showed a non-significant superior trend vs. Sculptra (no statistically significant difference vs. Sculptra; Figure 4B, Table S7 in Porcello 2024). In vitro comparison only; authors note the absence of orthogonal collagen quantification (e.g., proteomics, ELISA) and in vivo validation as key limitations 9. The comparative ranking of agents by neocollagenesis remains uncertain in humans.

A combined biostimulator systematic review (Tam et al. 2025; 29 studies meeting inclusion from 1,237 screened) found that combinations of CaHA or PLLA with energy-based devices (HIFU, fractional laser, microneedling) showed “notable improvements in skin texture, elasticity, and contouring” with adverse events in 15–30% of cases (mostly erythema, bruising, nodules) 10. The absolute benefit attributed specifically to CaHA vs the energy-based device comparator cannot be isolated from these combination studies.

DimensionStatus
Ca²⁺ fibroblast stimulation mechanism conserved in humans?Plausible; not directly demonstrated with ion chelation experiment in human tissue
Comparative neocollagenesis vs. PLLA or PCL in humans?Not established by blinded comparison; animal data favors PCL > CaHA for fibroblast proliferation 1 gap/contradictory-evidence
Long-term outcome (>18 months)?Sparse; CMC gel component lost in weeks; microsphere residual effect assumed but not tracked long-term gap/long-term-unknown

stub — CaHA filler warrants its own compound page when the Ca²⁺-fibroblast axis and combination-therapy evidence base is better characterized.

Comparative safety overview

AgentNodule profileDegradation timelineKey complication
PLLAHistorical: 12/94 cases (12.8%; intradermal, Lafaurie 2005); modern subcutaneous: 0.4% (4,483 treatments; Palm/Mayoral 2021) 1 gap/needs-replication12–18 monthsNodules (protocol-sensitive); persistent granulomas rare
PDLLASimilar to PLLA; amorphous form may offer more homogeneous degradation 1Faster than PLLA; ~6–12 months estimatedNodules; less characterized than PLLA
PCLUncommon with correct depth/technique; late granuloma documented 6S/M/L/E variants: ~1/2/3/4 yrLate granuloma (months to years post-injection)
PDONot well-characterized in microsphere form; faster degradation may reduce chronic granuloma risk~3–6 monthsLimited safety database; Zhou 2023 retraction does not affect safety claims (Zhou was cited for efficacy, not nodule rates)
CaHACaHA-HA hybrid combinations: enzymatic dissolution effective 6; pure CaHA nodules: resolution difficult~12–18 monthsVascular occlusion risk (particulate nature); intravascular injection → embolism

Shared safety concerns for all particulate injectables:

  • Vascular occlusion risk. All five agents are particulate; inadvertent intra-arterial injection carries embolic risk greater than clear solutions (HA, PN). Standard precautions (aspiration, low injection pressure, blunt cannula for danger zones) are essential.
  • Nodule management. PLLA and PCL nodules may respond to intralesional 5-fluorouracil, triamcinolone, or hyaluronidase (the last specifically for CaHA-HA hybrid products 6); pure CaHA and PCL nodules have limited non-surgical resolution options.
  • Injection depth. Too superficial placement consistently increases nodule risk across all agents; modern technique emphasizes subdermal/deep-dermal placement.

Recency search — R25 (2021–2026)

Searches conducted 2026-06-09 via PubMed eutils and Crossref:

  1. poly-L-lactic acid skin dermal filler rejuvenation collagen 2019–2026 → 28 hits; 8 on-topic papers triaged
  2. polycaprolactone skin dermal filler aging collagen 2019–2026 → 16 hits; 8 on-topic
  3. polydioxanone PDO microspheres collagen neocollagenesis aging 2019–2026 → 0 hits (limited English-language corpus)
  4. calcium hydroxylapatite Radiesse skin filler aging collagen 2019–2026 → 3 hits
  5. biostimulator injectable skin collagen 2021–2026 → 105 hits; 20 reviewed
  6. PLLA macrophage collagen fibroblast mechanism skin 2018–2026 → 5 hits; 3 integrated
  7. calcium hydroxylapatite CaHA Radiesse biostimulation fibroblast collagen skin 2018–2026 → 1 hit

High-priority hits integrated:

  • Tam et al. 2025 (doi:10.1007/s00266-024-04627-5) — systematic review (29 studies); combinations of CaHA/PLLA with energy-based devices; adverse event rate 15–30%; most relevant systematic review in the field post-Rho 2024. Integrated in CaHA subsection.
  • Yu et al. 2025 (doi:10.1007/s00266-025-04839-3) — in vivo rat PLLA collagen study; type III early / type I late collagen kinetics; myofibroblast transformation; integrated in PLLA mechanism section.
  • Huth et al. 2024 (doi:10.36849/JDD.7791) — 3D skin model PLLA-SCA; TGFB2/CXCL6/IL1B mechanistic chain for collagen I synthesis; integrated in shared mechanism section.
  • Nowag et al. 2024 (doi:10.1111/jocd.15928) — PLLA vs CaHA macrophage cytokine comparison in vitro; CCL1/TNFR2/MIP-1α/IL-8 PLLA-specific elevation; CaHA non-significant; key comparative mechanistic finding. Integrated in shared mechanism and CaHA sections.
  • Ianhez et al. 2024 (doi:10.1111/jocd.16343) — 55 biostimulator complication cases Brazil; nodule resolution poor across agents; CaHA-HA hybrids respond to hyaluronidase. Integrated in safety section.
  • Flores Rodríguez et al. 2026 (doi:10.7759/cureus.107800) — Cureus narrative review (low-tier; weight accordingly); covers all four agents; PCL neocollagenesis up to 24 months; PDLLA NRF2 detail. Integrated as supporting context only, not load-bearing for quantitative claims.
  • Porcello et al. 2024 (doi:10.3390/gels10060361) — in vitro fibroblast collagen assay (primary human dermal fibroblasts, 96 h); HAR vitamin B3-HA hydrogels showed significantly greater total collagen induction than Radiesse; non-significant superior trend vs Sculptra. Integrated in CaHA subsection. Note: the earlier seeder summary “comparably or superiorly to both Radiesse and Sculptra” was inaccurate — superiority to Sculptra was not statistically significant per Figure 4B/Table S7 of the paper; corrected during this verification pass.

PMID 37103107 (Zhou et al. 2023, PDO filler mouse + human): RETRACTED — retraction notice In Vivo 2024;38(3):1519, PMID 38688657. Excluded entirely from active citations. Was Rho 2024 ref [79] (general PDO context); the PDO > PLLA comparative collagen/TGF-β claim traces to Rho ref [80] = Kim CM 2019 (non-retracted). 8

No recent source contradicts the Rho 2024 framing of the shared biostimulatory mechanism. The Nowag 2024 comparative macrophage finding (CaHA elicits a significantly weaker early cytokine response than PLLA) is the most materially new mechanistic finding and was not available at Rho 2024 draft time. Tam 2025 is the first systematic review on biostimulator combinations. No large RCT (n>100) with a sham arm for any single agent was identified in the search window.

Limitations and gaps

  • No sham-injection-controlled RCT with histological endpoint for any agent. The entire clinical evidence base for biostimulators rests on uncontrolled series, photographic assessments, and ultrasound-based skin thickness measures. The needle-wound and carrier-gel effects are never subtracted. gap/needs-replication
  • Zhou 2023 retracted; PDO comparative claim traces to Kim CM 2019 (non-retracted). The claim that PDO > PLLA for Col1α1/Col3α1/TGF-β2/TGF-β3 induction traces to Rho 2024 ref [80] = Kim CM et al., J Cosmet Dermatol 2019;18(06):1893-1898, which is not retracted. Zhou et al. 2023 (PMID 37103107; retracted May–Jun 2024, In Vivo 38(3):1519, PMID 38688657) was Rho ref [79] used for general PDO efficacy context only; it is excluded from all active citations here. The Kim CM 2019 primary DOI was not independently confirmed against the full text in this session; tag gap/needs-replication until verified.
  • Quantitative claims traced to primary sources via Rho 2024 reference list (4,483 PLLA treatments / 0.4% nodule rate → Palm/Mayoral 2021 ref [57]; 12/94 nodules → Lafaurie 2005 ref [55]; Kim +27%/+21% skin thickness → Kim JS Aesthet Surg J 2019 ref [67]; 4-yr PCL particle retention → Kim J. Plast Reconstr Surg Glob Open 2020 ref [68]): primary DOIs identified but full texts not independently confirmed in this session. gap/needs-replication remains until those primaries are read directly.
  • Animal-to-human extrapolation for most mechanism data. The bulk of in vitro / in vivo mechanistic evidence is from rat or murine dermis; human-dermis-specific biopsy RCT data is absent. gap/needs-human-replication
  • Long-term outcomes beyond 4 years are unknown for all agents. Persistent particulate matter, late-emerging foreign-body giant cell granulomas, and durability of neocollagenesis benefit beyond the polymer degradation window are unstudied. gap/long-term-unknown
  • clinical-trials-active: null — ClinicalTrials.gov v2 API query not conducted for this class page in this session; re-query per the 6-month cadence.
  • No biological-age endpoint (epigenetic clock, transcriptomic skin age) has ever been measured for biostimulatory fillers. Whether the demonstrated neocollagenesis maps to a measurable reversal of skin biological age is entirely unknown. gap/no-mechanism

Cross-references

  • injectable-skin-boosters — umbrella class page (classification table, injection technique, umbrella regulatory overview, comparison with all other booster categories)
  • hyaluronic-acid — mechanism contrast (hydration/space-fill vs. biostimulation); HA filler comparison for neocollagenesis
  • pdrn — mechanistic contrast (A2A receptor pathway vs. foreign-body scaffold)
  • microneedling — the needle-wound confounder shared with all injectable biostimulators; sham-control design argument
  • dermatologic-resurfacing — energy-based collagen stimulation; combination protocols with biostimulators documented in Tam 2025
  • dermal-fibroblasts — primary effector cell; mechanism of TGF-β/SMAD activation; do not duplicate fibroblast biology here
  • skin-aging — the target phenotype; ECM deficit biostimulators address
  • col1a1 — type I collagen; primary neocollagenesis marker
  • col3a1 — type III collagen; early neocollagenesis marker; ratio with type I shifts during biostimulatory response
  • eln — elastin; secondary ECM target upregulated by PLLA/PCL biostimulatory response
  • tgf-beta-smad — the pathway through which TGF-β activates fibroblast collagen synthesis
  • loss-of-proteostasis — primary hallmark targeted (ECM architectural deficit in aged dermis)
  • chronic-inflammation — secondary target (M1→M2 polarization reduces local chronic inflammation)
  • altered-intercellular-communication — paracrine macrophage-to-fibroblast signalling axis
  • rho-2024-injectable-skin-boosters — synthesis anchor
  • matrix-gla-protein — mentioned here only to note disambiguation from vascular CaHA calcification biology

Footnotes

Footnotes

  1. rho-2024-injectable-skin-boosters · doi:10.1055/a-2366-3436 · PMID 39544509 · PMC11560330 (open access) · narrative review · Rho NK, Kim HS, Kim SY, Lee W · Archives of Plastic Surgery 2024;51(6):528–541 · synthesis anchor for injectable skin boosters; covers PLLA, PDLLA, PCL, PDO, CaHA mechanism, clinical data, safety, and injection technique. Many quantitative subagent claims in this page (nodule rates, skin thickness increases, particle degradation timelines) are drawn from this review; primary DOIs for those individual studies were not independently confirmed in this seeding session and are flagged gap/needs-replication. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26

  2. doi:10.7759/cureus.107800 · PMID 42211639 · PMC13214704 (open access) · narrative review — Cureus (low-tier; weight accordingly) · literature review of all four biostimulators (PLLA, PDLLA, PCL, CaHA) · PLLA/PDLLA: M1→M2 transition, type I/III collagen + elastin + angiogenesis; PCL: durable neocollagenesis up to 24 months + neovascularization; CaHA: more pronounced early inflammatory gene signature; all four: controlled inflammatory response with macrophage infiltration and possible foreign-body giant cells · Cureus 2026 Mar;18(3):e107800 · Flores Rodríguez JC et al. · narrative review only; no primary data; Cureus peer review is not equivalent to high-impact journals; use for contextual framing, not for quantitative claims ↩ ↩2 ↩3 ↩4

  3. doi:10.1111/jocd.15928 · PMID 37593832 · in vitro preclinical · primary human macrophages incubated with two dilutions (1:50 and 1:100) of CaHA or PLLA (no animal or human-tissue model) · CCL1 (p<0.001), TNFR2 (p<0.01), MIP-1α (p<0.05), IL-8 (p<0.001) significantly upregulated in M1 macrophages by PLLA vs. CaHA and unstimulated controls; M2 macrophages: MIP-1α and MIP-1β elevated by PLLA · Journal of Cosmetic Dermatology 2024 Jan;23(1):99–106 (published online 2023-08-18) · Nowag B, Schäfer D, Hengl T, Corduff N, Goldie K · in vitro only; n not specified per macrophage donor; no human tissue endpoint; Rho 2024 ref [82] gap/needs-human-replication ↩ ↩2 ↩3 ↩4

  4. doi:10.36849/JDD.7791 · PMID 38564382 · in vitro 3D skin model · macrophage-containing 3D human dermal equivalent injected once with PLLA-SCA · increased epidermal thickness at day 5 and 14; TGFB2, CXCL6, IL1B upregulated at day 14; IL1B and CXCL6 identified as collagen I synthesis mediators in fibroblasts · Journal of Drugs in Dermatology 2024;23(4):285–288 · Huth S, Huth L, Marquardt Y, Jansen M, Lin C, Bartneck M, Baron JM · 3D model; single injection; human-tissue construct; no sham/PBS control reported gap/needs-replication ↩ ↩2 ↩3

  5. doi:10.1007/s00266-025-04839-3 · PMID 40204932 · closed-access · in vivo · male Sprague-Dawley rats, intradermal injection (rat backs), PLLA microspheres vs crosslinked HA vs saline control; staining: H&E, Ki-67, Herovici, Sirius scarlet, immunofluorescence · PLLA increased type I and type III collagen; type III collagen stimulated early, transitioning to type I dominance in later stages via fibroblast-to-myofibroblast transformation; HA showed significant type I collagen stimulation (p<0.05) but no statistically significant impact on type III collagen; saline: no measurable increase in either collagen type · Aesthetic Plastic Surgery 2025 Jul;49(13):3803–3813 (online April 2025) · Yu H, Zhang Y-L, Chen Y, Dong Y-X, Hong W-J, Luo S-K · rat model only; not human skin; no aged-animal cohort; n per group not reported in abstract; full PDF closed-access (not_oa) — quantitative cytokine data and exact group n not independently confirmed from methods/results gap/needs-human-replication ↩ ↩2 ↩3

  6. doi:10.1111/jocd.16343 · PMID 38693639 · observational case series · n=55 biostimulator complication cases captured by dermatologic ultrasound specialists in Brazil; products: PLLA, CaHA, PCL · nodule formation dominant presentation (~1 month post-treatment); facial region most common; only 5/55 complete resolution; enzymatic dissolution effective specifically for CaHA+HA hybrid combinations; resolution attempts (saline, enzyme, laser) had variable success · Journal of Cosmetic Dermatology 2024;23(9):2972–2981 (online May 2024) · Ianhez M, Freire GGS, Sigrist RMS, Colpas PT, Faria IA, Parada MOAB, Miot HA · retrospective case series; Brazil-specific product mix; selection bias (ultrasound-specialist referral) gap/needs-replication ↩ ↩2 ↩3 ↩4 ↩5

  7. doi not independently confirmed — Kim CM, Kim BY, Hye Suh D, Lee SJ, Moon HR, Ryu HJ · “The efficacy of powdered polydioxanone in terms of collagen production compared with poly-L-lactic acid in a murine model” · J Cosmet Dermatol 2019;18(06):1893-1898 · Rho 2024 ref [80] · murine model; comparative PDO vs PLLA collagen induction; primary DOI not independently confirmed in this session gap/needs-replication ↩

  8. RETRACTED — doi:10.21873/invivo.13184 · PMID 37103107 · Zhou SY, Kang SM, Gu YJ et al. · In Vivo 2023;37(3):1093–1102 · originally described PDO filler biodegradation and neocollagenesis in mouse + human; reported PDO biodegradable in 12 weeks with superior neocollagenesis to HA · Retracted May–June 2024 — retraction notice: In Vivo 2024;38(3):1519, PMID 38688657; no reason stated in the retraction notice · Do NOT cite for any biological or clinical claim. Was Rho 2024 ref [79] (general PDO context only); the PDO > PLLA comparative collagen claim (Col1α1/Col3α1/TGF-β2/TGF-β3) traces to Rho ref [80] = Kim CM 2019, which is not retracted. ↩ ↩2

  9. doi:10.3390/gels10060361 · PMID 38920908 · PMC11203111 (open access) · in vitro · primary human dermal fibroblasts (96 h incubation); total collagen quantification (colorimetric Collagen Assay Kit MAK332); comparators: Radiesse® (CaHA+CMC, 5-fold diluted), Sculptra™ (PLLA, 1 vial in 5 mL water), JUVÉDERM VOLUMA® (HA control), PBS (sham control) · HAR-1 and HAR-3 (vitamin B3-functionalized cross-linked HA) induced significantly greater total collagen than Radiesse (p significant per Figure 4B/Table S7); non-significant superior trend vs. Sculptra (no statistically significant difference); both HAR products significantly outperformed VOLUMA and PBS · Gels 2024;10(6):361 · Porcello A, Chemali M, Marques C, Scaletta C, Lourenço K, Abdel-Sayed P, Raffoul W, Hirt-Burri N, Applegate LA, Laurent A · limitations: in vitro only; Radiesse required 5-fold dilution (assay well adhesion issue); no orthogonal validation (proteomics, ELISA); no in vivo confirmation; collagen is total collagen not type I/III-specific ↩

  10. doi:10.1007/s00266-024-04627-5 · PMID 39719485 · systematic review · 1,237 studies screened; 29 met inclusion criteria; biostimulators (PLLA, CaHA, PCL) combined with botulinum toxin, fillers, or energy-based devices (HIFU, fractional laser, microneedling) · CaHA/PLLA + energy-based devices → notable improvement in skin texture, elasticity, and contouring; adverse events 15–30% (erythema, bruising, nodules); authors note lack of understanding of synergistic mechanisms and recommend standardized protocols · Aesthetic Plastic Surgery 2025 May;49(5):2087–2099 (online Dec 2024) · Tam E, Choo JPS, Rao P, Webb WR, Carruthers JDA, Rahman E · combination studies only; cannot isolate biostimulator contribution from energy-device contribution gap/needs-replication ↩

Graph View

Backlinks